Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants

Free Radical Biology and Medicine

Volumn 26, Issue 7-8, 1999, Pages 892-904

  Aviram, Michael ^a   Rosenblat, Mira ^a   Billecke, Scott ^b   Erogul, John ^b   Sorenson, Robert ^b   Bisgaier, Charles L ^c   Newton, Roger S ^c   La Du, Bert ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antioxidants; Arylesterase; Free radicals; Glabridin; LDL; Lipid peroxidation; Lysophosphatidylcholine; Paraoxonase; Quercetin; Sulfhydryl group

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; AZO COMPOUND; COPPER; FREE RADICAL; GLABRIDIN; HYDROXYMERCURIBENZOIC ACID; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN; QUERCETIN; THIOL GROUP;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ENZYME ACTIVITY; ENZYME INACTIVATION; HYDROLYSIS; LIPID PEROXIDATION; OXIDATION; PRIORITY JOURNAL;

AMIDINES; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; COPPER SULFATE; ESTERASES; HOMOZYGOTE; HUMANS; KINETICS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALONDIALDEHYDE; OXIDANTS; OXIDATION-REDUCTION; PHENOLS; PHENOTYPE; QUERCETIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VITAMIN E;

EID: 0032921557     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(98)00272-X     Document Type: Article

References (37)

1. La Du B.N. Structural and functional diversity of paraoxonases. Nature Med. 2:1996;1186-1187.
2. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonases biochemistry, genetics and relationship to plasma lipoproteins. Current. Opin. Lipidol. 7:1996;69-76.
3. Mackness M.I., Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115:1995;243-253.
4. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J.M., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15:1995;1812-1818.
5. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32:1986;671-673.
6. Mackness M.I., Harty D., Bhatnager D., Winocour P.H., Arrol S., Ishola M., Durrington P.N. Serum paraoxonase activity in familial hypercholesterolemia and insulin dependent diabetes mellitus. Atherosclerosis. 86:1991;193-199.
7. Ruiz J., Blanche H., James R.W., Blatter-Garin M-C, Vaise C., Charpeutier G., Cohen N., Morabia A., Possa P., Froguel P. Gln-Arg 191 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
8. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln 191-Arg) is associated with coronary heart disease in Japanese noninsulin- dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:(7):1997;2257-2260.
9. Suehiro, T.; Makauchi, Y.; Yamamoto, M.; Arii, K.; Itoh, H.; Hamashige, N.; Hashimoto, K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 15:57(1):69-73; 1996.
10. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:1995;3005-3008.
11. Shih D.M., Gu L., Hama S., Xia Y., Navab M., Fogelman A.M., Lusis A.J. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97:1996;1630-1639.
12. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Teritto M.C., Lusis A.J., Shih D.M., Van Lenten B.J., Frank J.S., Demer L.L., Edwards P.A., Fogelman A.M. The Ying and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16:1996;831-842.
13. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N.J. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions A possible peroxidative role for paraoxonase . J. Clin. Invest. 101:1998;1581-1590.
14. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Fault K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low-density lipoprotein. J. Clin. Invest. 96:1995;2882-2891.
15. Aviram M., Billecke S., Sorenson R., Bisgaier C.L., Newton R.S., Rosenblat M., Erogul J., Dunlop C., La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities Selective action of human paraoxonase allozymes Q and R . Arterioscler. Thromb Vasc. Biol. 18:1998;1617-1624.
16. Augustinsson K.B., Heimburger G. Enzymatic hydrolysis of organophosphorus compounds. VI. Effect of metallic ions on the phosphoryl phosphatases of human serum and swine kidney. Acta. Chemica. Scandinavia. 9:1995;383-392.
17. Vitarius J.A., Sultatos L.G. Kinetic mechanism of the detoxification of the organophosphate paraoxon by human serum A-esterase. Drug Metab. Disp. 22:1994;472-478.
18. Nishio E., Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun. 236:1997;289-293.
19. La Du B.N., Adkins S., Kuo C.L., Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem. Biol. Interact. 87:1993;25-34.
20. Eckerson H.W., Romson J., Wyte C., La Du B.N. The human serum paraoxonase polymorphism Identification of phenotypes by their response to salts . Am. J. Hum. Genet. 35:1983;214-227.
21. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Drug. Met. Disp. 19:1991;100-106.
22. Kuo C.L., La Du B.N. Comparison of purified human and rabbit serum paraoxonases. Drug Metab. Disp. 23:1995;935-944.
23. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods. Enzymol. 52:1978;302-310.
24. El-Saadani M., Esterbauer H., El-Sayed M., Goher M., Nassar A.Y., Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J. Lipid Res. 30:1989;627-630.
25. Sorenson R.C., Primo-Parmo S.L., Kuo O.L., Adkins S., Lockridge O., La Du B.N. Reconsideration of the catalytic center and mechanism of mamalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. USA. 92:1995;7186-7191.
26. Frei B., Gaziano J.M. Content of antioxidants,pre-formed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and independent oxidation. J. Lipid Res. 34:1993;2135-2145.
27. Navab M., Hama-Levy S., Van Lenten B., Fonarow G.C., Cardinez C.J., Castellani L.W., Brennan M.L., Lusis A.J., Fogelman A.M. Mildly oxidized LDL induces an increased apolipoprotein J /paraoxonase ratio. J. Clin. Invest. 99:1997;2005-2019.
28. Bielicki J.K., Forte T.M., Mccall M.R. Minimally oxidized LDL is a potent inhibitor of lecithin cholesterol acyltransferase activity. J. Lipid Res. 37:1996;1012-1021.
29. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase Glutamine or Arginine at position 191, for the respective A or B allozymes . Am. J. Hum. Genet. 52:1993;598-608.
30. Suko A., Regnstrom J., Shah P.K., Cereck B., Nilsson J. Reactive oxygen intermediates and lysophosphatidylcholine are involved in oxidized LDL -induced activation of smooth muscle cell DNA synthesis. Arterioscler. Thromb. Vasc. Biol. 16:1996;194-200.
31. Aviram M. Oxidized LDL interaction with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur. J. Clin. Chem. Clin. Biochem. 34:1996;599-608.
32. Aviram, M. Antioxidants for restenosis and atherogenesis. In: Holmes, D. R; Serruys, P. W. eds. Current Review of Interventional Cardiology. 4th edition. (in press).
33. Belinky P.A., Aviram M., Mahmood S., Vaya J. Structural aspects of the inhibitory effect of glabridin on LDL oxidation. Free Rad. Biol. Med. 24:1998;1419-1429.
34. Hayek T., Fuhrman B., Vaya J., Rosenblat M., Belinky P., Coleman R., Elis A., Aviram M. Reduced progression of atherosclerosis in the apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin, or catechin, is associated with reduced susceptibility of LDL to oxidation and to aggregation. Arterioscler. Thromb. Vasc. Biol. 17:1997;2744-2752.
35. Fuhrman B., Buch S., Vaya J., Belinky P.A., Coleman R., Hayek T., Aviram M. Licorice extract and its major polyphenol glabridin protect low density lipoprotein against lipid peroxidation In vitro and ex-vivo studies in humans and in atherosclerotic apolipoprotein E - deficient mice . Am. J. Clin. Nutr. 66:1997;267-275.
36. Aviram M., Rosenblat M., Bisgaier C.L., Newton S.R. Atorvastatin and gemfibrozil metabolites, but not the parent drugs are potent antioxidants against lipoproteins oxidation. Atherosclerosis. 138:1998;271-280.
37. 2-modified LDL is taken up at enhanced rate by macrophages. Biochem. Biophys. Res. Commun. 185:1992;465-472.